How Quitting Smoking Can Quickly Lower Risk Of A-Fib

Updated Sep 14, 2024 | 02:00 AM IST

SummaryNew research reveals that quitting smoking quickly reduces the risk of atrial fibrillation (A-Fib). Former smokers have a significantly lower risk compared to current smokers, emphasizing the health benefits of quitting.
How Quitting Smoking Can Quickly Lower Risk Of A-Fib

How Quitting Smoking Can Quickly Lower Risk Of A-Fib

Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.

Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."

What is Atrial Fibrillation (A-Fib)?

A-Fib is a heart condition that affects the upper chambers of the heart, known as the atria. When these chambers beat irregularly, blood can pool and form clots, increasing the risk of stroke. Stroke is one of the most serious complications associated with A-Fib, and smoking is known to exacerbate this risk.

"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.

The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.

"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.

The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.

Tips for Quitting Smoking

Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:

1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.

2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.

3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.

4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.

5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.

6. Drinking water can help flush nicotine out of your system faster, reducing cravings.

7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.

Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.

End of Article

Lung Cancer Survival Improves By 71% In US: But 1 In 5 Patients Still Gets No Treatment

Updated Nov 18, 2026 | 06:00 PM IST

SummaryThe American Lung Association's annual report found that despite improved survival rates, 20.9% of lung cancer patients receive no treatment, only 29.3% are diagnosed early and just 24.4% of eligible people undergo screening.
Lung Cancer Survival Improves By 71% In US: But 1 In 5 Patients Still Gets No Treatment

Credit: iStock

Lung cancer remains the leading cause of cancer deaths in the US, with 229,410 new cases expected this year, according to a annual report from the American Lung Association's (ALA).

The Association's ninth annual State of Lung Cancer report stated that although five-year survival has improved, low screening rates, delayed diagnosis and unequal access to treatment remain major challenges.

Harold Wimmer, President and CEO of the ALA, said, “the national five-year survival rate has increased significantly, from 18.1% to 31.0%, and screening rates have also continued to rise.”

However, he warned that progress has not reached all communities equally.

“Awareness is still low and challenges remain. We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis.”

One In Five Lung Cancer Patients Receives No Treatment

Only 29.3% of lung cancer cases are diagnosed early. Rhode Island recorded the highest early diagnosis rate at 38%, while Hawaii had the lowest at 21.9%.

More concerning, 20.9% of patients received no treatment. The ALA identified potential barriers including lack of awareness, stigma, fatalism after diagnosis and treatment costs.

No-treatment rates ranged from 13.4% in Rhode Island to 36.7% in Nevada.

Only 1 In 4 Eligible People Gets Screened

Annual low-dose CT scans can detect lung cancer early in people at high risk. Yet only 24.4% of eligible Americans underwent screening.

Massachusetts recorded the highest screening rate at 38.7%, while South Dakota had the lowest at 13.5%.

Other Key Findings

  • The US is expected to record 229,410 new lung cancer cases this year, with an incidence rate of 52.1 per 100,000 people. Utah had the lowest rate (24.6), while Kentucky had the highest (83.9).
  • The five-year survival rate stands at 31%. Massachusetts recorded the highest rate (40.9%), while Alabama had the lowest (23.8%).
  • Only 21.4% of patients underwent surgery. Massachusetts had the highest surgical treatment rate (32.7%), while New Mexico had the lowest (12.7%).
  • Biomarker testing helps identify suitable targeted therapies and immunotherapies. Nineteen states mandate insurance coverage for comprehensive testing, seven require partial coverage, while 24 states and Washington, D.C., have no such mandate.
  • Racial disparities persist, with people of color less likely to receive early diagnoses or surgery and more likely to receive no treatment than white patients.

What Increases The Risk Of Lung Cancer?

Smoking is a major risk factor. Others include radon gas, air pollution and secondhand smoke. The ALA recommends radon testing, reducing air pollution and stronger tobacco-control measures, including smoke-free laws and access to smoking cessation services.

Why Is Lung Cancer Often Diagnosed Late?

Cleveland Clinic defines lung cancer as a malignant disease that happens when cells in the lung tissue grow out of control and form tumors. It is the leading cause of cancer deaths worldwide.

Lung cancer may cause no noticeable symptoms in its early stages. Symptoms can include persistent cough, coughing up blood, chest pain, unexplained weight loss, shortness of breath, recurrent chest infections and fatigue.

These symptoms should not be ignored. Early detection improves the chances of successful treatment, particularly before the cancer spreads.

End of Article

ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

Updated Nov 18, 2026 | 05:04 PM IST

SummaryIndia is facing widespread antibiotic resistance, with several drugs showing low effectiveness against bacteria such as E. coli, Klebsiella pneumoniae and Salmonella. The ICMR's 2025 report also flags resistance to powerful antibiotics, including carbapenems, across participating hospitals.
ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

Credit: iStock

Several antibiotics used to treat infections caused by E. coli and Klebsiella pneumoniae—bacteria linked to pneumonia, urinary tract and bloodstream infections—are showing low susceptibility in India, with resistance also reported to powerful drugs such as carbapenems, according to a new Indian Council of Medical Research (ICMR) report.

The newly released ICMR Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025 assesses the distribution of bacterial pathogens and their susceptibility to different antibiotics.

The surveillance covers Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, as well as Gram-positive bacteria such as Staphylococcus aureus and Enterococcus species.

For the first time, the report included data from 34 secondary-care hospitals, highlighting that antibiotic resistance is a concern beyond large, specialised hospitals.

The findings underscore the need for better diagnostics, responsible antibiotic use and stronger infection prevention.

"Antibiotic resistance is no longer a distant threat—it is affecting patients and families across India," Dr Neha Rastogi Panda, Senior Consultant, Infectious Diseases, Fortis Hospital, Gurugram, told HealthandMe.

Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO

Key Findings From The ICMR Report

The report highlighted several concerning resistance patterns across bacterial pathogens, including:

1. E. coli: Low susceptibility to cefotaxime and ceftazidime

The report showed that susceptibility of E. coli isolates to third-generation cephalosporins was low, with only 18.4% and 24.7% susceptible to cefotaxime and ceftazidime, respectively.

Low susceptibility was also observed among isolates from outpatient department (OPD) patients, suggesting that resistance to these antibiotics is widespread in the community and indicating a high prevalence of antibiotic-blocking enzymes.

2. K. pneumoniae: Low susceptibility to piperacillin-tazobactam and carbapenems

K. pneumoniae showed an alarmingly high resistance profile, with only 29.2% susceptible to piperacillin-tazobactam, 23–27% to third-generation cephalosporins, and only 35–40% to carbapenems.

Amikacin susceptibility was limited to 44.5%, while susceptibility to ceftazidime-avibactam was 37.7%. Tigecycline showed higher susceptibility, at 79.3%.

3. E. coli: Ceftriaxone susceptibility falls in secondary-care hospitals

Ceftriaxone susceptibility declined from 39.8% in Category I to 28.0% in Category II and 11.5% in Category III hospitals, indicating a high prevalence of resistance to third-generation cephalosporins even in smaller hospitals.

Meropenem susceptibility also declined across the three categories, from 80.3% to 77.5% and 67.1%, respectively.

Read more: Nearly 1 In 2 Patients Die, Treatment Costs Rise By 46%: ICMR Study Reveals Impact Of Drug-Resistant Infections

4. Acinetobacter baumannii: High carbapenem resistance

A high prevalence of carbapenem resistance was observed among A. baumannii, with 91.1% of revived isolates exhibiting carbapenem resistance, highlighting a substantial therapeutic and infection-control challenge.

OXA-23 was the predominant carbapenemase determinant, with frequent detection of OXA-23 and NDM co-profiles.

5. Salmonella Typhi and Salmonella Paratyphi A: Very low ciprofloxacin susceptibility

Fluoroquinolone susceptibility was lowest among the antibiotics assessed for both pathogens. Ciprofloxacin susceptibility was observed in only 2.0% of S. Typhi isolates and 0.4% of S. Paratyphi A isolates.

How Can We Prevent Antibiotic Resistance?

Dr Rastogi Panda warned that every time an antibiotic is misused, it increases the risk of making future infections harder to treat.

She advised people to:

  • Never take antibiotics without a doctor's prescription.
  • Never share antibiotics or use leftover tablets.
  • Take antibiotics exactly as prescribed.
  • Remember that antibiotics do not work against viral infections such as colds and flu.

"Cancer patients, ICU patients, the elderly and those with weakened immunity are particularly vulnerable. Responsible antibiotic use, vaccination and good hand hygiene can save lives. Protect antibiotics today, so they protect us tomorrow," the expert said.

End of Article

White House Drops Heidi Overton’s Nomination For US FDA Chief

Updated Nov 18, 2026 | 10:58 AM IST

SummaryHeidi Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.
White House Drops Heidi Overton’s Nomination For US FDA Chief

Credit: AP Photos

The White House has withdrawn the nomination of physician and presidential adviser Dr. Heidi Overton to lead the Food and Drug Administration (FDA), ending her bid for the top regulatory post just a day before a scheduled Senate committee vote.

Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.

“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy wrote on X shortly after the withdrawal.

A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation.”

Republican Opposition Threatened Her Confirmation

Also read: Meet Heidi Overton: Trump Set to Nominate White House Adviser to Lead FDA

The nomination faced growing resistance from Republican members of the 21-member Senate committee. Overton needed the support of all 12 Republicans to advance, assuming all 11 Democrats voted against her.

Several Republican senators had not committed to supporting her, including Cassidy, Susan Collins and Lisa Murkowski. The uncertainty left the White House struggling to secure the votes needed ahead of the November 18 committee hearing.

Cassidy, however, maintained that Overton was close to securing enough support. Calling the withdrawal “odd,” he said he had been having productive conversations with senators and believed she could have cleared both the committee and the full Senate.

What Went Wrong For Dr. Heidi Overton?

Read More: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation

Overton faced opposition over her positions on vaccine policy, abortion medication and vaping, exposing divisions among Republicans and the MAHA movement.

Vaccine policy: Cassidy questioned her role in Trump's efforts to change childhood vaccine recommendations, including splitting the combined measles, mumps and rubella (MMR) vaccine. Overton maintained that the MMR vaccine was safe and effective and said she would follow FDA safety requirements.

Mifepristone restrictions: Anti-abortion groups and Republican Sen. Josh Hawley questioned her commitment to tightening restrictions on mifepristone, the abortion pill. Meanwhile, Republican senators Susan Collins and Lisa Murkowski raised concerns about her strong anti-abortion positions.

Flavoured vapes: Overton faced criticism for her role in the administration's authorisation of fruit-flavoured e-cigarettes. Opponents even launched a campaign using the label “Heidi Vaperton” to urge senators to reject her nomination.

MAHA backlash: Some supporters of Robert F. Kennedy Jr.'s Make America Healthy Again movement accused Overton of being too close to corporate and agricultural interests. Former White House adviser Calley Means alleged that her decisions on glyphosate and flavoured vapes conflicted with Kennedy's agenda.

Who Is Dr. Heidi Overton?

Overton is a physician and former deputy director of the White House Domestic Policy Council. Before her nomination, she worked at the conservative think tank America First Policy Institute, where she eventually led its Health Policy Center.

She received her medical degree from the University of New Mexico, completed general surgery training at Johns Hopkins University and pursued clinical investigation research training at the Johns Hopkins Bloomberg School of Public Health.

She also served during Trump's first administration before joining the think tank.

Overton was involved in several prominent health policy initiatives under the current administration, including efforts to redesign the food pyramid, overhaul childhood vaccine recommendations and negotiate prescription drug pricing deals.

FDA Continues Under Acting Leadership

The withdrawal leaves the FDA without a Senate-confirmed commissioner. Acting Commissioner Kyle Diamantas has been leading the agency since Makary resigned in May.

The administration is now considering potential replacements, including Republican Senator Roger Marshall of Kansas, according to Reuters. No new nominee has been formally announced.

End of Article